Science & Technology Review
|
2023, 41(18): 58-66
• Exclusive:Cancer prevention and cure •
Advances of subsequent therapeutic strategies to overcome resistance to CDK4/6 inhibitors in breast cancer and its mechanisms
Full
MA Jiayi, YIN Wenjin, WU Ziping, LU Jingsong*
Affiliations
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Published: 2023-09-28
doi: 10.3981/j.issn.1000-7857.2023.18.008
Outline
This article provided an overview of current therapeutic strategies to overcome CDK4/6 inhibitor resistance in breast cancer and analyzed the clinical findings of CDK4/6 inhibitor cross-line therapy, novel oral SERDs, PI3K/AKT/mTOR inhibitors, ADC drugs, AURKA inhibitors, HDAC inhibitors, immunotherapeutic strategies and anti-senescence therapies after CDK4/6 inhibitor progression and the related mechanisms. Furthermore, we prospected the potential targets for clinical studies in the future.
cyclin-dependent kinase 4/6 inhibitor
/
advanced breast cancer
/
mechanisms of drug resistance
/
endocrine therapy
MA Jiayi, YIN Wenjin, WU Ziping, LU Jingsong.
Advances of subsequent therapeutic strategies to overcome resistance to CDK4/6 inhibitors in breast cancer and its mechanisms[J].
Science & Technology Review,
2023
, 41
(18)
: 58
-66
.
DOI: 10.3981/j.issn.1000-7857.2023.18.008
Year 2023 volume 41 Issue 18
PDF
902
222
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2023.18.008
- Receive Date:2023-05-26
- Online Date:2023-09-28
- Published:2023-09-28